Genmab A/S (GMAB)
Chart Events
Performance Outlook
| Previous Close | 37.01 |
| Open | 36.84 |
| Bid | 36.94 x 1100 |
| Ask | 36.97 x 1000 |
| Day's Range | 36.80 - 37.06 |
| 52 Week Range | 26.19 - 49.07 |
| Volume | |
| Avg. Volume | 663,624 |
| Market Cap | 24.307B |
| Beta (5Y Monthly) | 0.60 |
| PE Ratio (TTM) | 55.91 |
| EPS (TTM) | 0.66 |
| Earnings Date | N/A |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 40.70 |
- GlobeNewswire
Transactions in connection with share buy-back program
Company Announcement COPENHAGEN, Denmark; August 15, 2022 – Genmab A/S (Nasdaq: GMAB). On June 17, 2022 Genmab announced the initiation of a share buy-back program to mitigate dilution from warrant exercises and to honor our commitments under our Restricted Stock Units program. The share buy-back program is expected to be completed no later than August 31, 2022 and comprises up to 370,000 shares. The following transactions were executed under the program from August 8, 2022 to August 12, 2022: N
- Motley Fool
Genmab A/S (GMAB) Q2 2022 Earnings Call Transcript
Genmab is not under any obligation to update statements regarding the future, nor to confirm such statements in relation to actual results, unless this is required by law. Please also note that Genmab may hold your personal data as indicated by you as part of our Investor Relations outreach activities in order to update you on Genmab going forward. Please refer to our website for more information on Genmab and our privacy policy.
- GlobeNewswire
Genmab Announces Financial Results for the First Half of 2022
August 10, 2022 Copenhagen, Denmark; Interim Report for the First Six Months Ended June 30, 2022 Highlights Genmab and AbbVie Inc. (AbbVie) announced topline results for epcoritamab from the Phase 1/2 trial in patients with relapsed/refractory large B-cell lymphoma (LBCL)Genmab announced its intent to submit a biologics license application (BLA) to the U.S. Food and Drug Administration (U.S. FDA) for epcoritamab for the treatment of patients with relapsed/refractory LBCL, in the second half of 2
